Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2025-02-10 00:00:00 ET · period of report 2025-02-07 · accession 0001628280-25-004708 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-10 | 2025-02-07 | ARWR | Anzalone Christopher Richard | CEO, Dir | A - Grant | $20.10 | +9,550 | 3.77M | +0.3% | +$192.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-07 | A | A | 9,550 | $20.10 | 3,773,802 | D | — | — | (F1) Shares represent equity in lieu of part of his year-end cash bonus. (F2) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |